-
EP4247849
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4247849
| EP4247849 - METHODS OF TREATING CANCER WITH A COMBINATION OF TUCATINIB AND AN ANTI-PD-1/ANTI-PD-L1 ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 25.08.2023 Database last updated on 22.08.2024 | |
| Former | The international publication has been made Status updated on 27.05.2022 | ||
| Former | unknown Status updated on 24.12.2021 | Most recent event Tooltip | 19.01.2024 | Change: Validation states | published on 21.02.2024 [2024/08] | 19.01.2024 | Change - extension states | published on 21.02.2024 [2024/08] | Applicant(s) | For all designated states Seagen Inc. 21823 30th Drive S.E. Bothell, WA 98021 / US | For all designated states Peter MacCallum Cancer Institute 305 Grattan Street Melbourne, VIC 3000 / AU | [2023/39] | Inventor(s) | 01 /
PETERSON, Scott Bothell, Washington 98021 / US | 02 /
LOI, Sherene Camberwell, Victoria 3124 / AU | [2023/39] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/39] | Application number, filing date | 21824448.1 | 16.11.2021 | [2023/39] | WO2021US59534 | Priority number, date | US202063114797P | 17.11.2020 Original published format: US 202063114797 P | [2023/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2022108931 | Date: | 27.05.2022 | Language: | EN | [2022/21] | Type: | A2 Application without search report | No.: | EP4247849 | Date: | 27.09.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.05.2022 takes the place of the publication of the European patent application. | [2023/39] | Search report(s) | International search report - published on: | EP | 07.07.2022 | Classification | IPC: | C07K16/28, A61K31/517, A61K39/395, A61P35/00 | [2023/39] | CPC: |
C07K16/2818 (EP,IL,KR,US);
A61K31/517 (EP,IL,KR,US);
A61K39/39541 (EP,IL);
A61K39/39558 (EP,IL);
A61K45/06 (US);
A61P35/00 (EP,IL,KR,US);
| C-Set: |
A61K31/517, A61K2300/00 (EP);
A61K39/39541, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/39] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON KREBS MIT EINER KOMBINATION AUS TUCATINIB UND EINEM ANTI-PD-1/ANTI-PD-L1-ANTIKÖRPER | [2023/39] | English: | METHODS OF TREATING CANCER WITH A COMBINATION OF TUCATINIB AND AN ANTI-PD-1/ANTI-PD-L1 ANTIBODY | [2023/39] | French: | MÉTHODES DE TRAITEMENT DU CANCER AU MOYEN D'UNE ASSOCIATION DE TUCATINIB ET D'UN ANTICORPS ANTI-PD-1/ANTI-PD-L1 | [2023/39] | Entry into regional phase | 25.05.2023 | National basic fee paid | 25.05.2023 | Designation fee(s) paid | 25.05.2023 | Examination fee paid | Examination procedure | 25.05.2023 | Examination requested [2023/39] | 25.05.2023 | Date on which the examining division has become responsible | 04.01.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.11.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | by applicant | US4235871 | US4474893 | US4501728 | EP0216846 | US4683203 | US4683195 | WO8704462 | US4714681 | US4837028 | EP0323997 | EP0332435 | EP0338841 | US4902505 | US4925648 | US4957735 | WO9100360 | US5004697 | US5019369 | US5055303 | WO9203918 | WO9205793 | WO9208802 | WO9222653 | WO9222645 | WO9301227 | US5188837 | WO9317715 | US5254342 | US5268164 | US5271961 | WO9425585 | EP0629240 | US5413797 | US5498531 | US5506206 | US5514670 | US5534496 | US5545806 | US5545807 | US5569825 | US5573920 | US5591639 | US5601819 | US5625126 | US5633425 | US5658759 | US5661016 | US5733743 | US5741957 | US5750172 | US5756687 | WO9824884 | US5770429 | US5789650 | US5814318 | US5827690 | US5874299 | US5877397 | US5879936 | US5891693 | US5981216 | WO0109187 | WO0114424 | WO0243478 | WO2006121168 | WO2009097006 | US2010077497 | US7943743 | US8008449 | US8217149 | US8354509 | WO2013173223 | US8900587 | US2016272708 | US2016376367 | WO2017019846 | WO2017024465 | WO2017025051 | WO2017040790 | WO2017055547 | WO2017071625 | WO2017106656 | US2017210806 | WO2017133540 | WO2017166804 | US2017334995 | US9834606 | WO2018036472 | CN107840887 | WO2018103017 | WO2018200505 |